Top

Published in:

01-06-2010

Vasculogenic Mimicry: a New Prognostic Sign of Gastric Adenocarcinoma

Authors: Man Li, Yanjun Gu, Zhiguang Zhang, Shiwu Zhang, Danfang Zhang, Ali F. Saleem, Xiulan Zhao, Baocun Sun

Published in: Pathology & Oncology Research | Issue 2/2010

Abstract

Vasculogenic mimicry (VM) has been generally recognized as a new pattern of tumor neovascularization. It presents in many human malignancies. Till now, there is no report about VM in gastric adenocarcinoma (GAC). In this study, we collected 173 paraffin-embedded human GAC samples, with detailed follow-up and clinicopathologic data. CD31/ periodic acid-Schiff (PAS) double staining, immunohistochemical staining of CK8 & 18 and laminin were performed to validate the existence of VM in GAC. Microvascular density (MVD) and vasulogenic mimicry density (VMD) were counted respectively. VM was observed in 40 of the 173 GAC patients, especially in poorly differentiated GAC (P = 0.014). Patients with VM were prone to hematogenous metastasis and distant recurrence compared with patients without VM (P = 0.020, 0.029). Higher VMD values was also associated with hematogenous metastasis (P = 0.003). Immunohistochemical staining index (SI) of hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2, and MMP-9 were compared between the VM and non-VM group. The SI of four factors were all higher in the VM group than those of non-VM group (P = 0.000, 0.000, 0.004, 0.009, respectively). The Kaplan-Meier survival analysis showed that the VM group has shorter life span compared with non-VM group (P = 0.022). Cox proportional hazards model indicated that the presence of VM and TNM stage were independent predictors of poor prognosis (P = 0.039 and 0.004) for GAC. In conclusion, VM exists in GAC, especially in poorly differentiated GAC. Additionally, it is an unfavorable prognostic indictor for GAC. Hypoxia may play a role in VM formation in GAC.

Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739–752PubMed

Chang YS, di Tomaso E, McDonald DM et al (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97:14608–14613CrossRefPubMed

Chen X, Maniotis AJ, Majumdar D et al (2002) Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. Invest Ophthalmol Vis Sci 43:2533–2539PubMed

Folberg R, Mehaffey M, Gardner LM et al (1997) The microcirculation of choroidal and ciliary body melanomas. Eye 11:227–238PubMed

Folberg R, Hendrix MJ, Maniotis AJ (2000) Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156:361–381PubMed

Sood AK, Seftor EA, Fletcher MS et al (2001) Molecular determinants of ovarian cancer plasticity. Am J Pathol 158:1279–1288PubMed

Liu C, Huang H, Doñate F et al (2002) Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 62:5470–5475PubMed

Shirakawa K, Tsuda H, Heike Y et al (2001) Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 61:445–451PubMed

Sun B, Zhang S, Zhang D et al (2006) Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16:693–698PubMed

10.

Sun B, Zhang S, Zhao X et al (2004) Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 25:1609–1614PubMed

11.

van der Schaft DW, Hillen F, Pauwels P et al (2005) Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65:11520–11528CrossRefPubMed

12.

Sun B, Qie S, Zhang S et al (2008) Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol 39:846–856CrossRefPubMed

13.

Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112:508–525CrossRefPubMed

14.

Shirakawa K, Wakasugi H, Heike Y et al (2002) Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 99:821–828CrossRefPubMed

15.

Pisani P, Parkin DM, Bray F et al (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29CrossRefPubMed

16.

Tanigawa N, Amaya H, Matsumura M et al (1996) Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 56:2671–2676PubMed

17.

Zhao HC, Qin R, Chen XX et al (2006) Microvessel density is a prognostic marker of human gastric cancer. World J Gastroenterol 12:7598–7603PubMed

18.

Hasan J, Byers R, Jayson GC (2002) Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86:1566–1577CrossRefPubMed

19.

Issam Beyrouti M, Beyrouti R, Ben Amar M et al (2007) Linitis plastica. Presse Med 36:1782–1786CrossRefPubMed

20.

Sood AK, Fletcher MS, Coffin JE et al (2004) Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 190:899–909CrossRefPubMed

21.

Hendrix MJ, Seftor EA, Kirschmann DA et al (2003) Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci 995:151–161CrossRefPubMed

22.

Hess AR, Seftor EA, Seftor RE et al (2003) Phosphoinositide 3-kinase regulates membrane type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63:4757–4762PubMed

23.

Seftor RE, Seftor EA, Koshikawa N et al (2001) Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix / metallo-proteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61:6322–6327PubMed

24.

Sun B, Zhang D, Zhang S et al (2007) Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249:188–197CrossRefPubMed

25.

Seftor EA, Meltzer PS, Kirschmann DA et al (2002) Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 19:233–246CrossRefPubMed

26.

Höckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276CrossRefPubMed

27.

Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26:281–290CrossRefPubMed

28.

Cabuk D, Basaran G, Celikel C et al (2007) Vascular endothelial growth factor, hypoxia-inducible factor 1a and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology 72:111–117CrossRefPubMed

29.

Mizokami K, Kakeji Y, Oda S et al (2006) Clinicopathologic significance of hypoxia-inducible factor 1a overexpression in gastric carcinomas. J Surg Oncol 94:149–154CrossRefPubMed

30.

Griffiths EA, Pritchard SA, Welch IM et al (2005) Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer 41:2792–2805CrossRefPubMed

31.

Zhang J, Gao Q (2008) Morphology and mechanism research of gastric cancer vasculogenic mimicry. Journal of Chongqing Medical University 33:1063–1066

32.

Park SH, Han JK, Kim TK et al (1999) Unusual gastric tumors: radiologic-pathologic correlation. Radiographics 19:1435–1446PubMed

33.

Kunisaki C, Akiyama H, Nomura M et al (2006) Clinicopathologic properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res 26:639–646PubMed

34.

Adachi Y, Yasuda K, Inomata M et al (2000) Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 89:1418–1424CrossRefPubMed

35.

Strosberg JR, Nasir A, Hodul P et al (2008) Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res 2:113–125PubMed

36.

Sood AK, Fletcher MS, Hendrix MJ (2002) The embryonic-like properties of aggressive human tumor cells. J Soc Gynecol Investig 9:2–9CrossRefPubMed

37.

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMed

38.

Kim SJ, Rabbani ZN, Dewhirst MW et al (2005) Expression of HIF-1α CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49:325–335CrossRefPubMed

39.

Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696–1701CrossRefPubMed

Title: Vasculogenic Mimicry: a New Prognostic Sign of Gastric Adenocarcinoma
Authors: Man Li
Yanjun Gu
Zhiguang Zhang
Shiwu Zhang
Danfang Zhang
Ali F. Saleem
Xiulan Zhao
Baocun Sun
Publication date: 01-06-2010
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2010
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-009-9220-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Proximal-Type Epithelioid Sarcoma in the Groin Presenting as a Diagnostic Dilemma

Glutamate Promotes Cell Growth by EGFR Signaling on U-87MG Human Glioblastoma Cell Line

Is Predisposition for Nephroblastoma Linked to Polymorphisms of the WTX Gene?

Oxidant/Antioxidant Status, Lipids and Hormonal Profile in Overweight Women with Breast Cancer

IFN Gamma Gene Polymorphism May Contribute to the Susceptibility to CLL

Clinical Significance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 Receptors in Pancreatic Ductal Adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer